Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.

Vermeire, S ;
Hébuterne, X ;
Tilg, H ;
De Hertogh, G ;
Gineste, P ;
Steens, JM ;
,

Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium. Electronic address: Severine.Vermeire@uzleuven.be. Department of Gastroenterology and Clinical Nutrition, CHU of Nice, University Côte d'Azur, Nice, France. Department of Gastroenterology, Hepatology, Endocrinology & Metabolism, Medical University Innsbruck, Innsbruck, Austria. Department of Pathology, University Hospitals Leuven, Leuven, Belgium; Abivax, Paris, France.

Gastroenterology. 2021;(7):2595-2598.e3

Full text from:

Elsevier Science

Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.

Methodological quality

Metadata

Induction and Long-term Follow-up With ABX464 for Moderate-to-severe Ulcerative Colitis: Results of Phase IIa Trial.

Other resources

Methodological quality

Metadata